Dual Inhibition of MEK and PI3K Pathway in KRAS and BRAF Mutated Colorectal Cancers

被引:87
|
作者
Temraz, Sally [1 ]
Mukherji, Deborah [1 ]
Shamseddine, Ali [1 ]
机构
[1] Amer Univ Beirut, Med Ctr, Div Hematol Oncol, Dept Internal Med, Beirut 110 72020, Lebanon
来源
关键词
colorectal cancer; drug resistance; phosphatidylinositol; 3-kinase; mitogen-activated protein kinase; MEK; TUMOR-GROWTH; AZD6244; ARRY-142886; PHASE-I; SELUMETINIB AZD6244; KINASE INHIBITORS; PIK3CA MUTATION; K-RAS; COMBINATION; RESISTANCE; PHOSPHORYLATION;
D O I
10.3390/ijms160922976
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
Colorectal cancer (CRC) is a heterogeneous disease with multiple underlying causative genetic mutations. Genetic mutations in the phosphatidylinositol-3 kinase (PI3K) and the mitogen activated protein kinase (MAPK) pathways are frequently implicated in CRC. Targeting the downstream substrate MEK in these mutated tumors stands out as a potential target in CRC. Several selective inhibitors of MEK have entered clinical trial evaluation; however, clinical activity with single MEK inhibitors has been rarely observed and acquired resistance seems to be inevitable. Amplification of the driving oncogene KRAS(13D), which increases signaling through the ERK1/2 pathway, upregulation of the noncanonical wingless/calcium signaling pathway (Wnt), and coexisting PIK3CA mutations have all been implicated with resistance against MEK inhibitor therapy in KRAS mutated CRC. The Wnt pathway and amplification of the oncogene have also been associated with resistance to MEK inhibitors in CRCs harboring BRAF mutations. Thus, dual targeted inhibition of MEK and PI3K pathway effectors (mTOR, PI3K, AKT, IGF-1R or PI3K/mTOR inhibitors) presents a potential strategy to overcome resistance to MEK inhibitor therapy. Many clinical trials are underway to evaluate multiple combinations of these pathway inhibitors in solid tumors.
引用
收藏
页码:22976 / 22988
页数:13
相关论文
共 50 条
  • [31] PI3K and MEK Inhibition in Hypodiploid Acute Lymphoblastic Leukemia
    Comeaux, Evan
    Lin, Wenwei
    Chen, Taosheng
    Freeman, Burgess, III
    Mullighan, Charles G.
    BLOOD, 2016, 128 (22)
  • [32] FOXO proteins mediate adaptive resistance to PI3K inhibition in mucinous colorectal cancers
    Kuracha, Murali R.
    Thomas, Peter
    Loggie, Brian W.
    Govindarajan, Venkatesh
    CANCER RESEARCH, 2017, 77
  • [33] Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
    Bodo Haas
    Veronika Klinger
    Christina Keksel
    Verena Bonigut
    Daniela Kiefer
    Julia Caspers
    Julia Walther
    Maria Wos-Maganga
    Sandra Weickhardt
    Gabriele Röhn
    Marco Timmer
    Roland Frötschl
    Niels Eckstein
    Cancer Cell International, 18
  • [34] Inhibition of the PI3K but not the MEK/ERK pathway sensitizes human glioma cells to alkylating drugs
    Haas, Bodo
    Klinger, Veronika
    Keksel, Christina
    Bonigut, Verena
    Kiefer, Daniela
    Caspers, Julia
    Walther, Julia
    Wos-Maganga, Maria
    Weickhardt, Sandra
    Roehn, Gabriele
    Timmer, Marco
    Froetschl, Roland
    Eckstein, Niels
    CANCER CELL INTERNATIONAL, 2018, 18
  • [35] Analysis of PI3K pathway components in human cancers
    Daragmeh, Jamila
    Barriah, Waseim
    Saad, Bashar
    Zaid, Hilal
    ONCOLOGY LETTERS, 2016, 11 (04) : 2913 - 2918
  • [36] Enhanced cytotoxic activity of BRAF, MEK and PI3K inhibition with combination CDK4/6 inhibition in melanoma cells
    Zhang, Yanping
    Peng, Guangyong
    Hsueh, Eddy C.
    CANCER RESEARCH, 2018, 78 (13)
  • [37] Dual PI3K/mTOR inhibition in PIK3CA mutant pancreatic cancers
    Payne, Susan
    Depke, Mitchell
    Yueh, Alex
    Sharick, Joseph T.
    Favreau, Peter F.
    Pasch, Cheri A.
    Clipson, Linda
    Matkowskyj, Kristina A.
    Skala, Melissa
    Deming, Dustin A.
    CANCER RESEARCH, 2018, 78 (13)
  • [38] Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
    Lasolle, Helene
    Schiavo, Andrea
    Tourneur, Adrien
    Gillotay, Pierre
    de Faria da Fonseca, Barbara
    Ceolin, Lucieli
    Monestier, Olivier
    Aganahi, Benilda
    Chomette, Laura
    Kizys, Marina Malta Letro
    Haenebalcke, Lieven
    Pieters, Tim
    Goossens, Steven
    Haigh, Jody
    Detours, Vincent
    Maia, Ana Luiza Silva
    Costagliola, Sabine
    Romitti, Mirian
    ONCOGENE, 2024, 43 (03) : 155 - 170
  • [39] Differences in Signaling Patterns on PI3K Inhibition Reveal Context Specificity in KRAS-Mutant Cancers
    Stewart, Adam
    Coker, Elizabeth A.
    Palsterl, Sebastian
    Georgiou, Alexandros
    Minchom, Anna R.
    Carreira, Suzanne
    Cunningham, David
    O'Brien, Mary E. R.
    Raynaud, Florence, I
    de Bono, Johann S.
    Al-Lazikani, Bissan
    Banerji, Udai
    MOLECULAR CANCER THERAPEUTICS, 2019, 18 (08) : 1396 - 1404
  • [40] Dual targeting of MAPK and PI3K pathways unlocks redifferentiation of Braf-mutated thyroid cancer organoids
    Hélène Lasolle
    Andrea Schiavo
    Adrien Tourneur
    Pierre Gillotay
    Bárbara de Faria da Fonseca
    Lucieli Ceolin
    Olivier Monestier
    Benilda Aganahi
    Laura Chomette
    Marina Malta Letro Kizys
    Lieven Haenebalcke
    Tim Pieters
    Steven Goossens
    Jody Haigh
    Vincent Detours
    Ana Luiza Silva Maia
    Sabine Costagliola
    Mírian Romitti
    Oncogene, 2024, 43 : 155 - 170